Myriad Genetics, Inc.

As of November 4, 2019, Myriad Genetics, Inc. is considered overvalued and risky, with poor financial metrics such as a Price to Book Value of 0.67, a negative EV to EBITDA of -15.22, and a year-to-date stock return of -43.98%, significantly underperforming compared to its peers and the S&P 500.

As of November 4, 2019, Myriad Genetics, Inc. is considered undervalued with a price-to-book ratio of 0.67 and an EV to sales ratio of 0.54, despite ongoing losses reflected in its negative P/E ratio and operational challenges indicated by a ROCE of -13.04% and ROE of -9.36%, while its stock has significantly underperformed the S&P 500 with a year-to-date decline of 64.55%.

As of June 20, 2025, Myriad Genetics, Inc. has shifted to a bearish trend with moderate strength, indicated by daily moving averages, weekly KST, and Bollinger Bands, despite some mild bullish signals from the weekly MACD, and the stock's underperformance against the S&P 500 reinforces this outlook.

As of March 2022, the management team of Myriad Genetics, Inc. includes S. Louise Phanstiel (Independent Chairman), Paul Diaz (CEO), and several independent directors: Heiner Dreismann, Rashmi Kumar, Dennis Langer, Lee Newcomer, and Colleen Reitan. This team provides governance and strategic direction for the company.

Myriad Genetics, Inc. is a molecular diagnostic company focused on developing and marketing diagnostic tests in the Pharmaceuticals & Biotechnology sector. As of March 2025, it reported net sales of $196 million and has a market cap of $459.04 million.

As of Jun 18, Myriad Genetics, Inc. has a market capitalization of 459.04 million, with net sales of 831.30 million and a net profit of -101.40 million over the latest four quarters. The company reported shareholder's funds of 701.10 million and total assets of 1,027.60 million as of Dec 24.